Menu
← Oncology Approval Tracker
FDA DECISION ·
Orserdu
elacestrant · Stemline Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer progressing after at least one endocrine therapy line.
LAMPGEN ANALYSIS
Why it matters
This oral estrogen receptor degrader gave a molecularly defined group another endocrine option after progression.
What research teams should watch
Document the ESR1 result and previous endocrine treatment before determining whether the indication applies.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
ESR1-selected advanced or metastatic diseasePRIMARY RECORDS